Merck recently announces the initiation of the pivotal Phase 3 randomized MK-3543-006 clinical trial of Bomedemstat for Essential Thrombocythemia (ET). Lysine-specific demethylase 1 (LSD1) is critical for the regulation of hematopoietic stem and progenitor cells. Bomedemstat is an investigational small molecule irreversible inhibitor of LSD1 by suppressing progenitor cells during blood cell maturation. It is generally well tolerated in ET patients and demonstrates significant clinical activity as a monotherapy.
Bomedemstat has been granted Orphan Drug and Fast Track Designation for the treatment of ET and myelofibrosis (MF) by the U.S. FDA.
検索 
+86 21 5895 0110 
